MyFinsight
Home
Blog
About
Contact
Download
Download image
Net income
$22,592K
Accounts payable
$22,266K
Prepaid expenses and
other current assets
-$13,049K
Proceeds from issuance of
class a ordinary...
$6,389K
Share-based compensation
expense
$10,056K
Other long-term
liabilities
$6,794K
Deferred income taxes
$4,523K
Net amortization of
premiums and accretion of...
-$1,302K
Non-cash lease expense
$994K
Depreciation and
amortization expense
$468K
Other long-term
assets
-$125K
Net cash provided by
operating activities
$50,199K
Net cash provided by
financing activities
$6,073K
Canceled cashflow
$31,970K
Canceled cashflow
$316K
Net increase
(decrease) in cash and cash...
$24,356K
Canceled cashflow
$31,916K
Inventory
$18,246K
Accounts receivable, net
$7,630K
Accrued expenses,
accrued collaboration...
-$5,047K
Operating lease
liabilities
-$993K
Net gain on disposal
of property and...
$54K
Proceeds from the
maturities of short-term...
$145,656K
Payments in connection
with ordinary shares...
$316K
Net cash used in
investing activities
-$31,916K
Canceled cashflow
$145,656K
Purchases of short-term
investments
$177,411K
Purchases of property and
equipment
$161K
Back
Back
Cash Flow
source: myfinsight.com
Kiniksa Pharmaceuticals International, plc (KNSA)
Kiniksa Pharmaceuticals International, plc (KNSA)